INDIANAPOLIS and LYON, France, Dec. 19,
2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced a
worldwide licensing collaboration focused on developing an
ultra-rapid insulin, known as BioChaperone Lispro, for treatment in
people with type 1 and type 2 diabetes. BioChaperone Lispro relies
on Adocia's proprietary BioChaperone® technology and is currently
in Phase Ib studies.
Lilly and Adocia will develop BioChaperone Lispro with the goal
of optimizing glucose levels during and after meals. Potential
benefits of BioChaperone Lispro include greater flexibility in the
timing of insulin injections, lower variability of post-meal blood
glucose elevations, lower rates of hypoglycemia and better overall
glucose control.
Under the terms of the agreement, Lilly is responsible for
future development, manufacturing, and commercialization of
BioChaperone Lispro. The total up-front and milestone payments
could reach up to $570 million;
Adocia will receive a total upfront fee of $50 million with the potential for future
payments of up to $280 million if the
product reaches certain development and regulatory milestones, and
sales milestones up to $240 million,
as well as tiered sales royalties. Lilly shall also reimburse
Adocia for certain research and development expenses during the
terms of the agreement. A concentrated formulation of BioChaperone
Lispro is also part of the agreement.
"An ultra-rapid acting insulin, if approved by regulators, could
provide a new important treatment option for people with type 1 and
type 2 diabetes," said Enrique
Conterno, president, Lilly Diabetes. "An ultra-rapid acting
insulin would be a natural fit in our growing portfolio.
"It is a great day for Adocia and Lilly, a global leader in
diabetes treatment, to initiate a new collaboration for the
development of an innovative ultra-rapid formulation of insulin
lispro" said Gerard Soula, President
and CEO of Adocia. "We consider Lilly a key collaborator on this
project based on their extensive knowledge of insulin."
"We are proud that Lilly is collaborating on BioChaperone
Lispro, one of our lead products. We, Lilly and Adocia, will work
to develop innovative solutions to improve the lives of people with
diabetes," said Olivier Soula,
General Deputy Manager and R&D Director.
Adocia retains the right to develop and license its insulin
programs unrelated to prandial ultra-rapid insulin.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
http://newsroom.lilly.com/social-channels.
About Adocia
Adocia is a clinical-stage biotechnology
company that specializes in the development of innovative
formulations of already-approved therapeutic proteins. It has a
particularly strong expertise in the field of insulins. Adocia's
proprietary BioChaperone® technological platform is designed to
enhance the effectiveness and safety of therapeutic proteins and
their ease of use for patients. To learn more about Adocia, please
visit us at www.adocia.com.
C-LLY
This press release contains forward-looking statements about
the research collaboration between Adocia and Lilly related to
BioChaperone Lispro and reflects Lilly's current beliefs. However,
there are substantial risks and uncertainties in the process of
drug research, development, and commercialization. There is no
guarantee that the research collaboration will yield successful
results or that either company will achieve the anticipated
benefits, or that BioChaperone Lispro will achieve positive study
results, or will achieve regulatory approval. For further
discussion of these and other risks and uncertainties, see Lilly's
filings with the United States Securities and Exchange Commission.
Lilly undertakes no duty to update forward-looking
statements.
Logo-
http://photos.prnewswire.com/prnh/20031219/LLYLOGO
Logo- http://photos.prnewswire.com/prnh/20141218/165406LOGO
Refer to:
(317) 277-6524; lauren_zierke@lilly.com; Lauren Zierke (Lilly Corporate)
(317) 277-4021; kueterman_gregory_andrew@lilly.com; Greg Kueterman (Lilly Diabetes)
(33)4 72 610 610 ; g.soula@adocia.com; Gérard Soula (Adocia)
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-and-adocia-announce-alliance-to-co-develop-ultra-rapid-insulin-based-on-biochaperone-technology-300012349.html
SOURCE Eli Lilly and Company